These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32066909)

  • 1. Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
    Giatromanolaki A; Harris AL; Banham AH; Contrafouris CA; Koukourakis MI
    Br J Cancer; 2020 Apr; 122(8):1205-1210. PubMed ID: 32066909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
    Giatromanolaki A; Banham AH; Harris AL; Koukourakis MI
    Exp Lung Res; 2019; 45(3-4):76-83. PubMed ID: 31134811
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
    Boulle G; Velut Y; Mansuet-Lupo A; Gibault L; Blons H; Fournel L; Boni A; Cremer I; Wislez M; Duchatelle V; Trédaniel J; Hammond SA; Herbst R; Alifano M; Giraud P; Damotte D
    Eur J Cancer; 2020 Aug; 135():221-229. PubMed ID: 32610210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Pastorek J; Wykoff CC; Gatter KC; Harris AL
    Cancer Res; 2001 Nov; 61(21):7992-8. PubMed ID: 11691824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
    Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
    Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
    Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
    Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.
    Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI
    Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
    O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
    Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
    Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.